Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$208.03
-6.1%
$230.06
$204.95
$251.99
$59.73B0.351.65 million shs6.62 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$59.83
-3.2%
$80.14
$57.52
$141.99
$23.38B1.284.10 million shs6.55 million shs
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
$69.39
-4.9%
$71.74
$58.93
$95.25
$40.79B1.154.84 million shs7.51 million shs
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$393.73
-4.1%
$435.55
$393.50
$548.88
$31.91B1.39592,302 shs1.64 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
-6.12%-8.49%-7.20%-8.94%-14.64%
DexCom, Inc. stock logo
DXCM
DexCom
-3.19%-11.68%-27.00%-26.20%-56.80%
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
-4.99%-2.13%-4.81%-6.12%-25.41%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
-4.15%-5.32%-9.95%-5.25%-24.87%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
4.8895 of 5 stars
3.54.04.24.03.03.31.3
DexCom, Inc. stock logo
DXCM
DexCom
4.8542 of 5 stars
4.43.00.04.73.62.51.9
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
4.1966 of 5 stars
2.23.00.04.03.02.52.5
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
4.1626 of 5 stars
3.42.00.03.73.02.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
3.00
Buy$278.2933.77% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.89
Moderate Buy$99.8266.85% Upside
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
2.40
Hold$79.9515.23% Upside
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
2.80
Moderate Buy$533.7535.56% Upside

Current Analyst Ratings Breakdown

Latest DXCM, BDX, EW, and IDXX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/21/2025
DexCom, Inc. stock logo
DXCM
DexCom
Cfra Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
3/8/2025
DexCom, Inc. stock logo
DXCM
DexCom
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
3/4/2025
DexCom, Inc. stock logo
DXCM
DexCom
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$101.00 ➝ $104.00
2/14/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$278.00 ➝ $279.00
2/14/2025
DexCom, Inc. stock logo
DXCM
DexCom
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$75.00 ➝ $82.00
2/14/2025
DexCom, Inc. stock logo
DXCM
DexCom
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$99.00 ➝ $103.00
2/13/2025
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$88.00 ➝ $90.00
2/13/2025
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$68.00 ➝ $71.00
2/12/2025
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold ➝ Strong Sell
2/12/2025
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$85.00 ➝ $85.00
2/12/2025
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$70.00 ➝ $73.00
(Data available from 4/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$20.64B2.89$19.33 per share10.76$89.57 per share2.32
DexCom, Inc. stock logo
DXCM
DexCom
$4.03B5.80$1.51 per share39.75$5.38 per share11.12
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
$5.44B7.50$2.57 per share27.04$11.08 per share6.26
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$3.90B8.19$9.86 per share39.92$19.48 per share20.21
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$1.71B$6.0234.5613.301.638.47%15.74%7.29%5/1/2025 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$576.20M$1.4341.8424.322.3014.29%30.14%10.11%5/1/2025 (Estimated)
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
$4.17B$6.979.9525.234.8272.93%19.40%14.37%4/24/2025 (Estimated)
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
$887.87M$10.6736.9028.993.4122.78%55.82%26.48%5/7/2025 (Estimated)

Latest DXCM, BDX, EW, and IDXX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025N/A
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.28N/AN/AN/A$5.35 billionN/A
5/1/2025N/A
DexCom, Inc. stock logo
DXCM
DexCom
$0.33N/AN/AN/A$1.02 billionN/A
4/24/2025N/A
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
$0.60N/AN/AN/A$1.40 billionN/A
2/13/2025Q4 2024
DexCom, Inc. stock logo
DXCM
DexCom
$0.50$0.45-$0.05$0.38$1.10 billionN/A
2/11/2025Q4 2024
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
$0.55$0.59+$0.04$0.65$1.36 billionN/A
2/5/2025Q1 2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$3.00$3.43+$0.43$1.04$5.13 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
$4.162.00%+5.00%69.10%53 Years
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
N/AN/AN/AN/AN/A
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
N/AN/AN/AN/AN/A

Latest DXCM, BDX, EW, and IDXX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/28/2025
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
quarterly$1.041.67%3/10/20253/10/20253/31/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.69
1.13
0.63
DexCom, Inc. stock logo
DXCM
DexCom
0.59
1.47
1.28
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
0.06
3.46
2.89
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
0.28
1.31
0.95

Institutional Ownership

CompanyInstitutional Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
86.97%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
79.46%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
87.84%

Insider Ownership

CompanyInsider Ownership
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
0.36%
DexCom, Inc. stock logo
DXCM
DexCom
0.30%
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
1.29%
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
2.11%
CompanyEmployeesShares OutstandingFree FloatOptionable
Becton, Dickinson and Company stock logo
BDX
Becton, Dickinson and Company
77,000287.14 million286.10 millionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
7,600390.77 million389.60 millionOptionable
Edwards Lifesciences Co. stock logo
EW
Edwards Lifesciences
17,300587.87 million582.19 millionOptionable
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
10,80081.06 million80.16 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Becton, Dickinson and Company stock logo

Becton, Dickinson and Company NYSE:BDX

$208.03 -13.56 (-6.12%)
Closing price 04/4/2025 03:59 PM Eastern
Extended Trading
$210.18 +2.15 (+1.03%)
As of 04/4/2025 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

DexCom stock logo

DexCom NASDAQ:DXCM

$59.83 -1.97 (-3.19%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$59.50 -0.33 (-0.55%)
As of 04/4/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Edwards Lifesciences stock logo

Edwards Lifesciences NYSE:EW

$69.39 -3.59 (-4.92%)
Closing price 04/4/2025 03:59 PM Eastern
Extended Trading
$69.70 +0.31 (+0.45%)
As of 04/4/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

IDEXX Laboratories stock logo

IDEXX Laboratories NASDAQ:IDXX

$393.73 -17.03 (-4.15%)
Closing price 04/4/2025 04:00 PM Eastern
Extended Trading
$395.56 +1.83 (+0.47%)
As of 04/4/2025 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.